

# 正誤表

雑誌「産婦人科の実際」第 74 巻 7 号（2025 年 7 月号）につ き内容の更新がございました。下記のとおり訂正いたします。

2025 年 7 月

金原出版株式会社

## 記

| 頁    | 691                                                                                                                                                                                                                                  |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 訂正箇所 | 文献                                                                                                                                                                                                                                   |
| 訂正前  | 1) <u>Lorusso D et al : DS-6000a in advanced ovarian cancer : phase I expansion cohort (U101). Ann Oncol 34 (Suppl 2) : LBA77, 2023</u>                                                                                              |
|      | 2) Santin AD et al : Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS -03) : analysis in patients with advanced endometrial cancer. J Clin Oncol 42 : 3421-3429, 2024                    |
|      | 3) <u>Wang D et al : Sacituzumab tirumotecan in endometrial and ovarian cancer : phase 2. Ann Oncol 35 (Suppl 8) : Abstr 777, 2024</u>                                                                                               |
|      | 4) <u>Oaknin A et al : Datopotamab deruxtecan in gynecologic cancers : TROPION - PanTumor03. Ann Oncol 35 (Suppl 5) : S547-548, 2024</u>                                                                                             |
|      | 5) <u>Banerjee S et al : Rinatabart sesutecan (Rina-S) in platinum -resistant ovarian cancer : RAINFOL -01. Presented at : ESMO Gynaecol Cancers Congr ; Feb 23-25 ; Abstract LBA02, 2024</u>                                        |
|      | 6) <u>Gaillard S et al : Puxitatug samrotecan (AZD8205) in endometrial cancer : BLUESTAR study. Presented at : SGO Annu Meeting ; Mar 14 -17 ; Abstract 933087, 2025</u>                                                             |
| 訂正後  | 1) Moore KN et al : Raludotatug deruxtecan (R -DXd ; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC) : Subgroup analysis of a first -in-human phase I study. Ann Oncol 34 ( Suppl 2) : S510, 2023      |
|      | 2) Santin AD et al : Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS -03) : analysis in patients with advanced endometrial cancer. J Clin Oncol 42 : 3421-3429, 2024                    |
|      | 3) Wang D et al : Safety and efficacy of s acituzumab tirumotecan (sac -TMT) in patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) : A phase II study. Ann Oncol 35 (Suppl 2) : S548, 2024 |
|      | 4) Oaknin A et al : Datopotamab deruxtecan (Dato -DXd) in patients with endometr ial (EC) or ovarian cancer (OC) : Results from the phase II TROPION -PanTumor03 study. Ann Oncol 35(Suppl 2) : S547-548, 2024                       |
|      | 5) Lee EK et al : Rinatabart sesutecan (Rina -S) for patients with advanced ovarian cancer : Results from dose expansion cohort B1 of a phase 1/2 study. Presented at : SGO 2025 ; Abstract 809034, 2025                             |
|      | 6) Gaillard S et al : Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer : A first-in-human Phase 1/2a study. Presented at : SGO 2025 ; Abstract 933087, 2025                     |

以上